FrancophonIA/ELRC3.0 huggingface dataset:
English: Powder and solvent for prolonged-release suspension for injection 4 vials of 7 mg powder
Estonian: Toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti 4 viaali, igas 7 mg pulbrit
English: After reconstitution, 0.2 mL of suspension contains 2 mg (10 mg/mL).
Estonian: Pärast manustamiskõlblikuks muutmist sisaldab 0,2 ml suspensiooni 2 mg (10 mg/ml).
English: After reconstitution, 0.4 mL of suspension contains 4 mg (10 mg/mL).
Estonian: Pärast manustamiskõlblikuks muutmist sisaldab 0,4 ml suspensiooni 4 mg (10 mg/ml).
English: Somatropin Biopartners 2 mg should be reconstituted with 0.4 mL solvent.
Estonian: Somatropin Biopartners 2 mg tuleb muuta manustamiskõlblikuks 0,4 ml lahustiga.
English: Somatropin Biopartners 7 mg should be reconstituted with 0.9 mL solvent.
Estonian: Somatropin Biopartners 7 mg tuleb muuta manustamiskõlblikuks 0,9 ml lahustiga.
English: The vial contains an overfill of somatropin powder to allow the withdrawal of up to 4 mg (0.4 mL suspension) of somatropin when reconstituted.
Estonian: Viaal sisaldab somatropiini pulbri liiga, mis tagab kuni 4 mg (0,4 ml suspensiooni) manustamiskõlblikuks muudetud somatropiiniannuse kättesaadavuse.
English: The vial should be turned upside down, with the syringe in and the tip of the needle should be placed in the solvent.
Estonian: Viaal koos sisestatud süstlaga tuleb põhjaga ülespoole pöörata nii, et nõel jääb lahustisse.
English: Apply gentle pressure to the plunger until a small drop of suspension appears at the end of the needle.
Estonian: Vajutage õrnalt kolvile, kuni nõela tippu tekib väike tilk.
English: After preparation, 1 mL of suspension contains 20 mg somatropin (20 mg/mL).
Estonian: Pärast manustamiskõlblikuks muutmist sisaldab 1 ml suspensiooni 10 mg somatropiini (20 ml/mg).
English: - Somatropin Biopartners 20 mg: 20 mg (60 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a green flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl).
Estonian: - Somatropin Biopartners 20 mg: 20 mg (60 RÜ) somatropiini pulbrit klaasviaalis, suletud punnkorgi (butüülkummist) ning rohelise eemaldatava, alumiinium-plastikust kattega ja 1,5 ml lahustit (keskmise ahelaga triglütseriidid) klaasviaalis, suletud punnkorgiga (butüülkummist).
English: The 20-mg vial contains an overfill of somatropin powder to allow the withdrawal of up to 20 mg (1 mL suspension) of somatropin when reconstituted.
Estonian: 20 mg viaal sisaldab somatropiini pulbri liiga, mis tagab kuni 20 mg (0,5 ml suspensiooni) manustamiskõlblikuks muudetud somatropiiniannuse kättesaadavuse.
English: After preparation, 0.4 mL of suspension contains 4 mg somatropin (10 mg/mL).
Estonian: Pärast manustamiskõlblikuks muutmist sisaldab 0,4 ml suspensiooni 4 mg somatropiini (10 mg/ml).
English: Common: Nipple pain
Estonian: Sage: ninaverejooks
English: Powder and solvent for prolonged-release suspension for injection 4 vials of 4 mg powder
Estonian: Toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti 4 viaali, igas 4 mg pulbrit
English: With the exception of injection site related reactions and the formation of antibodies to rhGH which were reported more frequently in children than in adults the safety profile of Somatropin Biopartners is similar for children and adults.
Estonian: Somatropin Biopartners'i ohutusprofiil on nii lastel kui täiskasvanutel sarnane, v.a süstekoha reaktsioonid ja rhGH-vastaste antikehade moodustumine, mida esines lastel täiskasvanutest sagedamini.
English: After preparation, 0.5 mL of suspension contains 10 mg somatropin (20 mg/mL).
Estonian: Pärast manustamiskõlblikuks muutmist sisaldab 0,5 ml suspensiooni 10 mg somatropiini (20 mg/ml).
English: - Somatropin Biopartners 7 mg: 7 mg (21 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a light-blue flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl).
Estonian: - Somatropin Biopartners 7 mg: 7 mg (21 RÜ) somatropiini pulbrit klaasviaalis, suletud punnkorgi (butüülkummist) ning helesinise eemaldatava, alumiinium-plastikust kattega ja 1,5 ml lahustit (keskmise ahelaga triglütseriidid) klaasviaalis, suletud punnkorgiga (butüülkummist).
English: After preparation, 0.2 mL of suspension contains 2 mg somatropin (10 mg/mL).
Estonian: Pärast manustamiskõlblikuks muutmist sisaldab 0,2 ml suspensiooni 2 mg somatropiini (10 mg/ml).
English: To avoid this, always change the injection site between injections.
Estonian: Selle vältimiseks muutke iga kord süstekohta.
English: Somatropin Biopartners 10 mg should be reconstituted with 0.7 mL solvent.
Estonian: Somatropin Biopartners 10 mg tuleb muuta manustamiskõlblikuks 0,7 ml lahustiga.
English: INFORMATION IN BRAILLE Somatropin Biopartners 7 mg
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Somatropin Biopartners 7 mg
English: - Somatropin Biopartners 2 mg: 2 mg (6 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a yellow flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in a glass vial with a rubber stopper (butyl).
Estonian: - Somatropin Biopartners 2 mg: 2 mg (6 RÜ) somatropiini pulbrit klaasviaalis, suletud punnkorgi (butüülkummist) ning kollase eemaldatava, alumiinium-plastikust kattega ja 1,5 ml lahustit (keskmise ahelaga triglütseriidid) klaasviaalis, suletud punnkorgiga (butüülkummist).
English: - Somatropin Biopartners 4 mg: 4 mg (12 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a pink flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl).
Estonian: - Somatropin Biopartners 4 mg: 4 mg (12 RÜ) somatropiini pulbrit klaasviaalis, suletud punnkorgi (butüülkummist) ning roosa eemaldatava, alumiinium-plastikust kattega ja 1,5 ml lahustit (keskmise ahelaga triglütseriidid) klaasviaalis, suletud punnkorgiga (butüülkummist).
English: Injecting the suspension
Estonian: Suspensiooni süstimine
English: INFORMATION IN BRAILLE Somatropin Biopartners 4 mg
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Somatropin Biopartners 4 mg
English: INFORMATION IN BRAILLE Somatropin Biopartners 2 mg
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Somatropin Biopartners 2 mg
English: Each vial of powder delivers 20 mg somatropin; each vial of solvent contains 1.5 mL liquid.
Estonian: Ühest pulbriga viaalist saadakse 20 mg somatropiini, iga viaal lahustiga sisaldab 1,5 ml vedelikku.
English: Number of injections per dose
Estonian: Süstide arv annuse kohta
English: D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
Estonian: D. RAVIMPREPARAADI OHUTU JA EFEKTIIVSE KASUTAMISE TINGIMUSED JA PIIRANGUD
English: Malignancies
Estonian: Pahaloomulised kasvajad
English: Patient bodyweight (kg)
Estonian: Patsientide erirühmad Neeru- või maksakahjustus
English: INFORMATION IN BRAILLE Somatropin Biopartners 20 mg
Estonian: VÄLISPAKENDI TEKST SOMATROPIN BIOPARTNERS 20 MG
English: - Somatropin Biopartners 10 mg: 10 mg (30 IU) somatropin as powder in a glass vial closed with a rubber stopper (butyl) and a light-green flip-off cap (aluminium and plastic) and 1.5 mL solvent (medium chain triglycerides) in glass vial with a rubber stopper (butyl).
Estonian: - Somatropin Biopartners 10 mg: 10 mg (30 RÜ) somatropiini pulbrit klaasviaalis, suletud punnkorgi (butüülkummist) ning helerohelise eemaldatava, alumiinium-plastikust kattega ja 1,5 ml lahustit (keskmise ahelaga triglütseriidid) klaasviaalis, suletud punnkorgiga (butüülkummist).
English: Holding the needle against the inside vial wall, the entire contents of the syringe should be injected into the powder vial.
Estonian: Kogu süstlas olev vedelik tuleb süstida pulbriviaali, hoides nõela vastu viaali siseseina.
English: Each vial of powder delivers 7 mg somatropin; each vial of solvent contains 1.5 mL liquid.
Estonian: Ühest pulbriga viaalist saadakse 7 mg somatropiini, iga viaal lahustiga sisaldab 1,5 ml vedelikku.
English: A 1 mL graduated syringe with 19 Gauge or wider needle should be used for withdrawing the solvent from its vial.
Estonian: Lahusti viaalist väljatõmbamiseks tuleb kasutada 1 ml gradueeritud süstalt, millel on 19 G või suurema läbimõõduga nõel.
English: NAME OF THE MEDICINAL PRODUCT Somatropin Biopartners 7 mg powder and solvent for prolonged-release suspension for injection
Estonian: RAVIMPREPARAADI NIMETUS Somatropin Biopartners 7 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti
English: Pack size: 4 vials of powder and 4 vials of solvent.
Estonian: Pakendi suurus: 4 viaali pulbriga ja 4 viaali lahustiga.
English: You should not use Somatropin Biopartners if you are pregnant or are trying to become pregnant.
Estonian: Kui te olete rase või püüate rasestuda, ei tohi te Somatropin Biopartners'it kasutada.
English: NAME OF THE MEDICINAL PRODUCT Somatropin Biopartners 2 mg powder and solvent for prolonged-release suspension for injection
Estonian: RAVIMPREPARAADI NIMETUS Somatropin Biopartners 2 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti
English: Somatropin Biopartners 7 mg powder for prolonged-release suspension for injection somatropin
Estonian: Somatropin Biopartners 7 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber somatropiin s.c.
English: 1 vial of powder and 1 vial of solvent.
Estonian: 1 viaal pulbriga ja 1 viaal lahustiga.
English: Somatropin Biopartners 4 mg powder for prolonged-release suspension for injection somatropin
Estonian: Somatropin Biopartners 4 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber somatropiin s.c.
English: NAME OF THE MEDICINAL PRODUCT Somatropin Biopartners 4 mg powder and solvent for prolonged-release suspension for injection
Estonian: RAVIMPREPARAADI NIMETUS Somatropin Biopartners 4 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One vial delivers 7 mg of somatropin* (corresponding to 21 IU) After reconstitution, 0.7 mL of suspension contains 7 mg somatropin (10 mg/mL).
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Ühest viaalist saadakse 7 mg somatropiini* (vastab 21 RÜ-le).
English: Treatment should be discontinued if there is evidence of tumour
Estonian: Kasvaja aktiviseerumise korral tuleb ravi katkestada.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One vial delivers 20 mg of somatropin* (corresponding to 60 IU) After reconstitution, 1 mL of suspension contains 20 mg somatropin (20 mg/mL).
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Ühest viaalist saadakse 20 mg somatropiini* (vastab 60 RÜ-le).
English: Egg phospholipids
Estonian: - Epilepsiaravis kasutatavad ravimid.
English: Somatropin Biopartners 20 mg powder for prolonged-release suspension for injection somatropin
Estonian: Somatropin Biopartners 20 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber somatropiin s.c.
English: Shelf-life after reconstitution with solvent
Estonian: Kõlblikkusaeg pärast lahustiga manustamiskõlblikuks muutmist
English: Each vial of powder delivers 2 mg somatropin; each vial of solvent contains 1.5 mL liquid.
Estonian: Ühest pulbriga viaalist saadakse 2 mg somatropiini, iga viaal lahustiga sisaldab 1,5 ml vedelikku.
English: Psychiatric disorders Very rare: insomnia*
Estonian: Väga harv: unetus*
English: Somatropin Biopartners 2 mg powder for prolonged-release suspension for injection somatropin
Estonian: Somatropin Biopartners 2 mg toimeainet prolongeeritult vabastav süstesuspensiooni pulber somatropiin s.c.
English: Each vial of powder delivers 10 mg somatropin; each vial of solvent contains 1.5 mL liquid.
Estonian: Ühest pulbriga viaalist saadakse 10 mg somatropiini, iga viaal lahustiga sisaldab 1,5 ml vedelikku.
English: Each vial of powder delivers 4 mg somatropin; each vial of solvent contains 1.5 mL liquid.
Estonian: Ühest pulbriga viaalist saadakse 4 mg somatropiini, iga viaal lahustiga sisaldab 1,5 ml vedelikku.
English: Subcutaneous use
Estonian: Raviaegne jälgimine
English: INFORMATION IN BRAILLE Somatropin Biopartners 10 mg
Estonian: Somatropin Biopartners 10 mg
English: Powder: Vial (type I glass) closed with a rubber stopper (butyl) and a yellow flip-off cap (aluminium and plastic).
Estonian: Pulber: Klaasviaal (tüüp I), suletud punnkorgi (butüülkummist) ning kollase eemaldatava, alumiinium-plastikust kattega.
English: Pregnancy
Estonian: Abiained
English: Common: Nausea
Estonian: Sage: hüpertensioon
English: Powder: Vial (type I glass) closed with a rubber stopper (butyl) and a pink flip-off cap (aluminium and plastic).
Estonian: Pulber: Klaasviaal (tüüp I), suletud punnkorgi (butüülkummist) ning roosa eemaldatava, alumiiniumplastikust kattega.
English: Powder: Vial (type I glass) closed with a rubber stopper (butyl) and a green flip-off cap (aluminium and plastic).
Estonian: Pulber: Klaasviaal (tüüp I), suletud punnkorgi (butüülkummist) ning rohelise eemaldatava, alumiinium-plastikust kattega.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION One vial delivers 4 mg of somatropin* (corresponding to 12 IU) After reconstitution, 0.4 mL of suspension contains 4 mg somatropin (10 mg/mL).
Estonian: KVALITATIIVNE JA KVANTITATIIVNE KOOSTIS Ühest viaalist saadakse 4 mg somatropiini* (vastab 12 RÜ-le).
English: Somatropin Biopartners 10 mg powder for prolonged-release suspension for injection.
Estonian: Somatropin Biopartners 10 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti
English: Somatropin Biopartners 20 mg powder and solvent for prolonged-release suspension for injection
Estonian: Somatropin Biopartners 20 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti
English: Somatropin Biopartners 20 mg powder and solvent for prolonged-release suspension for injection somatropin
Estonian: Somatropin Biopartners 20 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti somatropiin
English: Powder: Vial (type I glass) closed with a rubber stopper (butyl) and a light-blue flip-off cap (aluminium and plastic).
Estonian: Pulber: Klaasviaal (tüüp I), suletud punnkorgi (butüülkummist) ning helesinise eemaldatava, alumiinium-plastikust kattega.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/13/849/002 4 vials of powder and 4 vials of solvent
Estonian: EU/1/13/849/002 4 pulbriviaali ja 4 lahustiviaali 13.
English: Solvent: Vial (Type I glass) closed with a rubber stopper (butyl) and a flip-off cap (aluminium and plastic).
Estonian: Lahusti: Klaasviaal (tüüp I), suletud punnkorgi (butüülkummist) ning alumiinium-plastikust kattega.
English: - disposal box for used syringes and needles
Estonian: - Suukaudne östrogeen või muud suguhormoonid.
English: Somatropin Biopartners 2 mg powder and solvent for prolonged-release suspension for injection somatropin
Estonian: Somatropin Biopartners 2 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber ja lahusti somatropiin
English: Apply gentle pressure to the plunger to get rid of the bubbles.
Estonian: Mullidest vabanemiseks vajutage õrnalt kolvile.
English: Somatropin Biopartners 10 mg powder and solvent for prolonged-release suspension for injection somatropin
Estonian: Somatropin Biopartners 10 mg toimeainet prolongeeritult vabastava süstesuspensiooni pulber somatropiin s.c.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/13/849/003 4 vials of powder and 4 vials of solvent
Estonian: EU/1/13/849/003 4 pulbriviaali ja 4 lahustiviaali 13.
English: Further information on Doptelet can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/doptelet.
Estonian: Lisateave Dopteleti kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/doptelet.
English: It is available as 20-mg tablets.
Estonian: Seda turustatakse 20 mg tablettidena.
English: Treatment with Doptelet should start at least 10 days before the procedure.
Estonian: Doptelet-ravi peab algama vähemalt 10 päeva enne protseduuri.
English: Other information about Doptelet
Estonian: Muu teave Dopteleti kohta
English: What measures are being taken to ensure the safe and effective use of Doptelet?
Estonian: Mis meetmed võetakse, et tagada Dopteleti ohutu ja efektiivne kasutamine?
English: Doptelet (avatrombopag)
Estonian: Doptelet (avatrombopaag)
English: The European Medicines Agency decided that Doptelet's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Dopteleti kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The dose is 2 or 3 tablets (depending on the platelet count at the start of treatment), daily for 5 days.
Estonian: Annus on 2 või 3 tabletti (sõltuvalt trombotsüütide sisaldusest ravi alguses), iga päev 5 päeva jooksul.
English: What is Doptelet and what is it used for?
Estonian: Mis on Doptelet ja milleks seda kasutatakse?
English: Doptelet (avatrombopag) EMA/243810/2019
Estonian: Doptelet (avatrombopaag) EMA/243810/2019
English: As for all medicines, data on the use of Doptelet are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Dopteleti kasutamise kohta pidevat järelevalvet.
English: For more information about using Doptelet, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Dopteleti kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The medicine is for use in patients having an invasive procedure (a medical procedure that involves cutting into or puncturing the skin or inserting instruments into the body).
Estonian: Ravim on ette nähtud kasutamiseks patsientidel, kellel on ees invasiivne protseduur (meditsiiniline protseduur, millega kaasneb nahasisselõike või -punktsiooni tegemine või instrumendi organismi viimine).
English: Side effects reported with Doptelet are carefully evaluated and any necessary action taken to protect patients.
Estonian: Dopteleti kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The most common side effect with Doptelet (which may affect up to 1 in 10 people) is tiredness.
Estonian: Dopteleti kõige sagedam kõrvalnäht (võib esineda kuni 1 patsiendil 10st) on väsimus.
English: A blood test on the day of the procedure is necessary to ensure that the platelet count is adequate and not unexpectedly high.
Estonian: Protseduuri päeval on vaja vereanalüüsiga kontrollida, et trombotsüütide sisaldus oleks piisav, kuid mitte liiga suur.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Doptelet have been included in the summary of product characteristics and the package leaflet.
Estonian: Dopteleti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Two main studies in 435 patients with low levels of platelets due to long-standing liver disease found Doptelet effective at increasing platelet levels before an invasive procedure.
Estonian: Kahes põhiuuringus (435 patsienti, kellel oli kauaaegse maksahaiguse tõttu väike leukotsüütide sisaldus) selgus, et Doptelet on efektiivne trombotsüütide sisalduse suurendamisel enne invasiivset protseduuri.
English: What are the risks associated with Doptelet?
Estonian: Mis riskid Dopteletiga kaasnevad?
English: Doptelet is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease.
Estonian: Doptelet on ravim, mida kasutatakse tugeva verejooksu ennetamiseks kroonilisest maksahaigusest põhjustatud trombotsütopeeniaga täiskasvanutel.
English: Any unwanted effects during treatment with Doptelet were thought to result from patients' medical condition and the nature of the invasive procedure for which it was used.
Estonian: Uuringutes ilmnenud Dopteleti ravi ajal esinenud kõrvalnähud olid arvatavasti tingitud patsientide terviseseisundist ja nende invasiivsete protseduuride olemusest, mille jaoks ravimit kasutati.
English: For the full list of side effects and restrictions with Doptelet, see the package leaflet.
Estonian: Dopteleti kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The active substance in Doptelet, avatrombopag, attaches to the same receptors as thrombopoietin, helping to increase the platelet count.
Estonian: Dopteleti toimeaine avatrombopaag seondub samade retseptoritega kui trombopoetiin, aidates suurendada trombotsüütide sisaldust.
English: Patients with thrombocytopenia have reduced number of platelets (components in the blood that help it to clot), which can cause excessive bleeding.
Estonian: Trombotsütopeeniaga patsientidel on trombotsüütide ehk vereliistakute (vere hüübimises osalevate vererakkude) vähesus, mis võib põhjustada tugevat verejooksu.
English: Studies have found that Doptelet reduced the need for platelet transfusions or other rescue treatments to prevent excessive bleeding before an invasive procedure and for up to 7 days afterward.
Estonian: Uuringutes selgus, et Doptelet vähendas enne invasiivset protseduuri ja kuni 7 päeva hiljem tugeva verejooksu ennetamiseks trombotsüütide ülekande või muude päästeprotseduuride vajadust.
English: In the body, a hormone called thrombopoietin stimulates the production of platelets by attaching to receptors (targets) in the bone marrow.
Estonian: Hormoon trombopoetiin stimuleerib organismis trombotsüütide teket, seondudes retseptoritega (sihtmärgiga) luuüdis.
English: An overview of Doptelet and why it is authorised in the EU
Estonian: Ülevaade ravimist Doptelet ja ELis müügiloa väljastamise põhjendus
English: Doptelet contains the active substance avatrombopag.
Estonian: Doptelet sisaldab toimeainena avatrombopaagi.
English: Among patients with more severe thrombocytopenia, 67% of those given Doptelet 60 mg daily did not require a transfusion or rescue procedure compared with 29% of those who received placebo.
Estonian: Raskema trombotsütopeeniaga patsientidest oli neid, kes ei vajanud vereülekannet ega päästeprotseduuri, ööpäevas 60 mg ravimit Doptelet võtnute seas 67% ja platseeborühmas 29%.
English: In these studies, 88% of patients who received Doptelet 40 mg daily did not require a transfusion or rescue procedure compared with 36% of patients who were given placebo (a dummy treatment).
Estonian: Nendes uuringutes oli patsiente, kes ei vajanud vereülekannet ega päästeprotseduuri, ööpäevas 40 mg ravimit Doptelet võtnute seas 88% ja platseebot (näiv ravim) võtnute seas 36%.
English: What benefits of Doptelet have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Dopteleti kasulikkus?
English: How is Doptelet used?
Estonian: Kuidas ravimit Doptelet kasutatakse?
English: The platelet count increased in patients treated with Doptelet.
Estonian: Dopteletiga ravitud patsientidel suurenes trombotsüütide sisaldus.
English: How does Doptelet work?
Estonian: Kuidas Doptelet toimib?
English: Doptelet can only be obtained with a prescription.
Estonian: Doptelet on retseptiravim.
English: The main measure of effectiveness was the number of patients who did not require a transfusion of platelets or other treatment ('rescue procedure') to prevent excessive bleeding after starting Doptelet treatment and for up to 7 days after their invasive procedure.
Estonian: kuni 7 päeva pärast invasiivset protseduuri tugeva verejooksu ennetamiseks trombotsüütide ülekannet ega muud ravi (edaspidi „päästeprotseduur“).
English: 10 bottles
Estonian: 10 pudelit
English: Member State EU/EEA
Estonian: ELi/EMP liikmesriik
English: It is ineffective against Enterobacteriaceae.
Estonian: Tülosiin on Enterobacteriaceae vastu ebaefektiivne.
English: Treatment durations beyond three weeks
Estonian: Ravi kestus üle kolme nädala
English: 3, Vyt and Hommez (2006) 4, MARAN (2008)
Estonian: Vyt ja Hommez (2006) 4, MARAN (2008)
English: 53000 LAVAL France
Estonian: 53000 LAVAL Prantsusmaa
English: Applicant/Marketing authorisation holder
Estonian: Müügiloa taotleja/hoidja Tootenimetus